Literature DB >> 17577723

Motor recovery after Guillain-Barré syndrome in childhood.

Fernando Ortiz-Corredor1, Marta Peña-Preciado, Jorge Díaz-Ruíz.   

Abstract

PURPOSE: To determine the clinical factors that modify the recovery time for gait after Guillain-Barré syndrome (GBS) in childhood.
METHOD: Medical records of patients admitted to Instituto de Ortopedia Infantil Roosevelt (IOIR) between years 1991 and 2001, were reviewed. Age, sex, cranial nerve impairment, requirement of assisted ventilation, number of days of assisted ventilation, muscular strength at day 10 of the disease, presence of quadriplegia, intravenous infusion of human gamma globulins (IVIG), were taken as independent variables. The number of needed days to reach Hughes State III was taken as the major outcome. First, univariate analysis was performed and with the factors that showed a statistically significant association with recovery time, multiple linear regression analysis and Cox regression were also performed.
RESULTS: Data of 332 children under 15 years old was collected. (Mean age: 7.1 years). A sample of 215 children was gathered for the study, all of them were regarded as functional states IV or V. Acute Motor Axonal Neuropathy (AMAN) was found in 30% of all cases. In the univariate analysis Cranial nerve impairment, requirement of assisted ventilation, presence of quadriplegia and presence of non-excitable motor nerves were associated with delayed motor recovery time. Patients who received IVIG reached Hughes state III faster than those who received only support treatment. This finding, that was more important in the presence of Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), lost its value in the Cox regression analysis. In the multivariate analysis, muscular strength, assessed at day 10 of the disease was the most important predictor to determine motor recovery. The presence of quadriplegia was strongly associated with a delayed recovery time. Relative risk: 3.3 (95% Confidence Interval 2.1 - 5.2).
CONCLUSIONS: Muscular strength at day 10 of the disease is the most useful clinical factor to determine prognosis of motor recovery in children who have suffered Guillain-Barré syndrome.

Entities:  

Mesh:

Year:  2007        PMID: 17577723     DOI: 10.1080/09638280701240326

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  4 in total

Review 1.  Guillain-Barré syndrome in Colombia: where do we stand now?

Authors:  María P Mahecha; Ernesto Ojeda; Daniel A Vega; Juan C Sarmiento-Monroy; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Correlative study between C-reactive protein, clinical severity, and nerve conduction studies in Guillain-Barrè syndrome.

Authors:  Yosria A Altaweel; Sawsan Abdelaziz; Hala A Fathy; Shimaa AbdelBadea
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-04-25

3.  Impact of the COVID-19 Pandemic on the Frequency, Clinical Spectrum and Outcomes of Pediatric Guillain-Barré Syndrome in India: A Multicentric Ambispective Cohort Study.

Authors:  Divyani Garg; Rajinder K Dhamija; Aditya Choudhary; Ritu Shree; Sujit Kumar; Priyanka Samal; Abhishek Pathak; Pamidimukkala Vijaya; Yareeda Sireesha; Sruthi S Nair; Sanjay Sharma; Soaham Desai; Human P Sinha; Ayush Agarwal; Ashish Upadhyay; M V Padma Srivastava; Rohit Bhatia; Awadh K Pandit; Rajesh K Singh; Alisha Reyaz; P M Yogeesh; Manish Salunkhe; Vivek Lal; Manish Modi; Gagandeep Singh; Monika Singla; Samhita Panda; Maya Gopalakrishnan; Inder Puri; Sudhir Sharma; Bismay Kumar; Prashant K Kushwaha; Harshadkumar Chovatiya; Teresa Ferreira; Sanjeev K Bhoi; Manish Bhartiya; Subhash Kaul; Anuja Patil; Neeharika L Mathukumalli; Madhu Nagappa; P Praveen Sharma; Aneesh Basheer; Dileep Ramachandran; Neetha Balaram; Jospeh Sebastian; Venugopalan Y Vishnu
Journal:  Ann Indian Acad Neurol       Date:  2021-11-17       Impact factor: 1.383

4.  Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Authors:  Juan-Sebastian Franco; David Vizcaya
Journal:  Pharmacol Res Perspect       Date:  2020-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.